Reuters: Hot Stocks: Gilead combo hepatitis C pill shown effective in small trial

Reuters: Hot Stocks Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Gilead combo hepatitis C pill shown effective in small trial May 2nd 2013, 14:01 Thu May 2, 2013 10:01am EDT May 2 (Reuters) - Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study. The data could help Gilead, whose shares rose 4 percent, remain in the lead among drugmakers racing to develop better medicines for the potentially dangerous condition that also require far shorter durations of treatment. Based on the favorable results, Gilead said it plans to conduct a third late-stage study of the fixed-dose combination tablet, which pairs the drugs sofosbuvir and ledipasvir. (Reporting By Ransdell Pierson; Editing by Gerald E. McCormick)

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions